Bold Move: The Founder Who Funded Herself
Nine hundred and twenty million dollars later, it has enough runway to operate through 2029 without needing a buyer, a partner, or anyone else's permission.
Abivax had a choice that most founders never get to face honestly. Take the acquisition offer — clean exit, someone else's problem, board applause — or raise the money, keep the keys, and bet on yourself all the way to the American market. The French biotech chose the second path. Nine hundred and twenty million dollars later, it has enough runway to operate through 2029 without needing a buyer, a partner, or anyone else's permission.
That is not a small decision. That is the entire game.
The mechanism behind it is worth understanding, because it applies far beyond pharma. When you raise enough capital to be genuinely independent, you change your negotiating position in every conversation that follows. Acquirers lowball you when they sense desperation — when they know your runway is short, your board is restless, and your next financing round is uncertain. The moment you remove that pressure, the dynamic reverses. You are no longer someone who needs a deal. You are someone who might do a deal, if the price reflects reality. That shift in posture is worth more than most people realise when they are still in the middle of building something.
There is a lesson here that has nothing to do with biotech. Every founder, every freelancer, every career professional is running some version of the same calculation. How much capital — in money, in skills, in relationships — do you need to stop making decisions from fear rather than strategy? The number is different for everyone. But the principle is identical: you cannot negotiate well when you cannot walk away. And you cannot walk away when you are broke.
The mistake most ambitious people make is confusing activity with position. They are always raising, always pitching, always closing the next thing — but they never pause to ask whether they have built enough independence to actually choose. Abivax chose. The CEO told CNBC the cash haul lets them prepare for a solo U.S. launch instead of relying on a buyer. Read that sentence again slowly. *Instead of relying.* That is the ambition benchmark.
If you are building something in Malta or anywhere else — a company, a practice, a career pivot — the question worth sitting with is not "how do I grow faster." It is "how do I get to the position where I can say no." If you are still mapping what that takes financially, the Malta grants landscape is broader than most people assume, and non-dilutive capital is always better than giving away equity under pressure.
Build the runway first. The launch will wait.
